Getting drugs past the neuroprotective blood-brain barrier (BBB) has been a perplexing problem and formidable challenge for researchers and pharmaceutical companies alike. Hesperos’s creation of a microfluidic model capable of mimicking in vivo characteristics of the … Read More
